• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Dr. Reddy's Laboratories Ltd ADR (NY: RDY )

    78.76 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EDT, Oct 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 104
    Open 78.76
    Bid (Size) 77.23 (2)
    Ask (Size) 79.47 (5)
    Prev. Close 78.76
    Today's Range 78.76 - 78.76
    52wk Range 63.72 - 84.46
    Shares Outstanding 166,301,231
    Dividend Yield 1.24%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Market Alert: Dr. Reddy’s Labs Reports New Data for Aurigene CAR-T Phase 1, Gets Approvals for Phase 2 Trials Progression
    Via AB Newswire
    Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
    From Aurigene Oncology Limited
    Via Business Wire

    Performance

    YTD
    +11.20%
    +11.20%
    1 Month
    -1.07%
    -1.07%
    3 Month
    +0.69%
    +0.69%
    6 Month
    +8.48%
    +8.48%
    1 Year
    +17.97%
    +17.97%

    More News

    Read More
    Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    Dr. Reddy's Laboratories – Elliott Wave Technical Analysis
    Via Talk Markets
    Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again?
    Via Investor's Business Daily
    Organon Stock Sees Relative Strength Rating Rise To 91
    Via Investor's Business Daily
    Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
    Via Talk Markets
    Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
    Via Investor's Business Daily
    Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    Dr. Reddy’s Q1FY25 Financial Results
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
    Via MarketBeat
    Should Quality-Oriented Investors Explore DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)?
    Via Chartmill
    Dr. Reddy's Labs Stock Sees Improved Technical Strength
    Via Investor's Business Daily
    Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M
    Via Benzinga
    Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
    From Aurigene Pharmaceutical Services Ltd.
    Via Business Wire
    Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High.
    Via Investor's Business Daily
    Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
    From Dr. Reddy's Laboratories Ltd.
    Via Business Wire
    Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
    From Alvotech
    Via GlobeNewswire
    RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024
    Via InvestorPlace
    Dr. Reddy’s Q4 & Full Year FY24 Financial Results
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
    From Dr. Reddy's Laboratories Ltd.
    Via Business Wire
    Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.